BI-7273

Target: This ligand targets bromodomain-containing protein 9 (BRD9) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for bromodomain-containing protein 9 (BRD9). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings bromodomain-containing protein 9 (BRD9) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated BRD4 Degradation: BI-7273 can be used as a ligand component in PROTAC designs to recruit BRD4 to the E3 ligase complex, enabling ubiquitination and proteasomal degradation. This application supports systematic optimization of linker length and attachment chemistry to maximize target engagement, degradation potency, and selectivity in BRD4-dependent cellular models.

• E3 Ligase Recruitment Optimization: BI-7273-derived conjugates can be explored across different E3 ligase recruiters to tune degradation efficiency and kinetics. By varying the E3-binding module and PROTAC architecture, researchers can map how ligase expression and cellular context influence BRD4 turnover, supporting rational design of chimeras with improved degradation durability.

• Mechanism-Driven Degrader Profiling: BI-7273-enabled PROTACs can be used to dissect degradation mechanisms, including dependency on proteasome activity and ubiquitin–ligase engagement. Combining time-course immunoblotting with rescue experiments (e.g., proteasome or ubiquitination pathway perturbation) helps distinguish degradation from transcriptional downregulation and clarifies the pathway governing BRD4 loss.

• Structure–Activity Relationship Studies: BI-7273 can serve as a starting ligand for SAR campaigns where linker composition, attachment site, and stereochemistry are systematically varied. These studies aim to correlate physicochemical and conformational parameters with degradation potency, ternary complex stabilization, and off-target effects, guiding development of PROTACs that achieve robust BRD4 degradation with minimal collateral protein loss.

BI-7273 is a BET bromodomain target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of BI-7273 is characterized by primary or secondary amine/basic nitrogen centers. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.